Decisions about when to start or switch a therapy often depend on the frequency with which individuals are monitored or tested. For example, the optimal time to switch antiretroviral therapy depends on the frequency with which HIV-positive individuals have HIV RNA measured. This paper describes an approach to use observational data for the comparison of joint monitoring and treatment strategies and applies the method to a clinically relevant question in HIV research: when can monitoring frequency be decreased and when should individuals switch from a first-line treatment regimen to a new regimen? We outline the target trial that would compare the dynamic strategies of interest and then describe how to emulate it using data from HIV-positive...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
BACKGROUND: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The limited a...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
When a clinical treatment fails or shows suboptimal results, the question of when to switch to anoth...
The benefits of immunologic and virologic monitoring for the management of HIV-positive individuals ...
BackgroundClinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive ...
OBJECTIVE To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies i...
Altres ajuts: This research was supported by NIH grant R01 AI073127; by NIH grant T32 AI007433 from ...
Data collected in a routine clinical setting are frequently used to compare antiretroviral treatment...
Objective: To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies in ...
BACKGROUND Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive...
It is still unclear under which conditions temporary combined antiretroviral therapy (cART) results ...
Data collected in a routine clinical setting are frequently used to compare antiretroviral treatment...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
BACKGROUND: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The limited a...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
When a clinical treatment fails or shows suboptimal results, the question of when to switch to anoth...
The benefits of immunologic and virologic monitoring for the management of HIV-positive individuals ...
BackgroundClinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive ...
OBJECTIVE To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies i...
Altres ajuts: This research was supported by NIH grant R01 AI073127; by NIH grant T32 AI007433 from ...
Data collected in a routine clinical setting are frequently used to compare antiretroviral treatment...
Objective: To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies in ...
BACKGROUND Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive...
It is still unclear under which conditions temporary combined antiretroviral therapy (cART) results ...
Data collected in a routine clinical setting are frequently used to compare antiretroviral treatment...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
BACKGROUND: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The limited a...